US20020077758A1 - System for control of blood processor - Google Patents
System for control of blood processor Download PDFInfo
- Publication number
- US20020077758A1 US20020077758A1 US09/302,487 US30248799A US2002077758A1 US 20020077758 A1 US20020077758 A1 US 20020077758A1 US 30248799 A US30248799 A US 30248799A US 2002077758 A1 US2002077758 A1 US 2002077758A1
- Authority
- US
- United States
- Prior art keywords
- blood processor
- blood
- preparation unit
- chamber
- script
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B13/00—Control arrangements specially designed for centrifuges; Programme control of centrifuges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0442—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0442—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
- B04B2005/0485—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation with a displaceable piston in the centrifuge chamber
Definitions
- This invention relates to a method and system for controlling a blood processor. To be more particular, this invention is especially applicable to a blood processor that produces fibrin sealant. In its most specific embodiment, the invention is a method and system for controlling a blood processor to produce autologous fibrin sealant.
- a blood processor may be understood, in general terms, as a machine that performs some process on blood.
- the blood may be human blood.
- a simple centrifuge may thus be thought of as a primitive blood processor.
- Blood processors range in complexity from very simple to very complex.
- the complexity of a blood processor may be thought of as being in direct relation to the number, the kind, and the delicacy of the processes it performs.
- the separation of red blood cells with a centrifuge is, by itself, a fairly simple process.
- a blood processor to perform only such a separation needs only relatively simple controls, such as an on/off switch, a speed setting, or the like.
- a highly complex apparatus for processing blood might require a myriad of controls.
- ASIC application specific integrated circuit
- An ASIC is disadvantageous, however, in the respect that it cannot be freely modified. In a highly complex blood processor, capable of performing many different operations and steps, this is a disadvantage because new procedures or modifications of old procedures may be desired. A blood processor with only an ASIC cannot be freely modified to execute such procedures.
- a blood processor is provided with a computer and memory, and external to the blood processor there is provided a general purpose computer system programmed with a convenient interface for creating scripts; the general purpose computer system translates the scripts into code of a custom interpretive language adapted to be interpreted by the computer in the blood processor, and the script of custom interpretive language instructions is written into the memory of the blood processor.
- multiple scripts are stored in the blood processor, and a barcode or the like on a disposable blood preparation unit indicates to the blood processor which of the multiple scripts should be invoked.
- FIG. 1 shows, in simplified schematic form, a preferred embodiment of the invention.
- FIG. 2 shows, in simplified schematic form, a blood processor according to the invention.
- FIG. 3 shows, in simplified schematic form, an external computer featuring a user interface and script generator according to the invention.
- FIG. 4 shows a blood processor including a bar code reader according to one embodiment of the invention.
- FIG. 5 shows an example of a part of a script according to one embodiment of the invention.
- a blood processor 100 is provided with a microprocessor 110 and a memory 120 .
- An external computer 200 has a blood processor interface 210 , a script generator 220 , and a user interface 230 .
- the external computer 200 is linked to the blood processor 100 .
- the blood processor interface 210 of the external computer 200 is operably linked to write information into the memory 120 of the blood processor 100 .
- the microprocessor 110 accesses the memory 120 to read the script of custom interpretive language instructions.
- the blood processor 100 is provided with a low level hardware interface 130 to which the microprocessor 110 is operably linked.
- the low level hardware interface 130 provides an interface whereby the microprocessor 110 may independently control a plurality of devices 140 of the blood processor 100 .
- devices means sensors, detectors, motors, actuators, displays, solenoids, or the like.
- Control of a device 140 may include receiving the input from a sensor or detector, driving a motor, actuator, display, or solenoid, or generally providing inputs to or taking output from any device 140 .
- the blood processor 100 has, in memory 120 , a program or set of programs readable by the microprocessor 110 .
- the microprocessor 110 operates according to the program read from the memory 120 .
- an input from one of the devices 140 will be used to initiate the blood processing procedure.
- a blood processor 100 may have a start button.
- the start button is a kind of device 140 .
- the start button when activated, may output an electrical signal in response to the activation. This electrical signal passes to the low level hardware interface 130 and may be provided as an interrupt to the microprocessor 110 .
- the microprocessor 110 may command the plurality of devices 140 in accordance with the program steps defined in the memory 120 of the blood processor 100 .
- the program steps may be thought of as predefined scripts which the microprocessor 110 must follow.
- the scripts stored in the memory 120 of the blood processor 100 are not generally intelligible by an unaided human.
- the program steps that comprise the scripts are in a custom interpretive language specially adapted to the blood processor 100 .
- the scripts are not created inside the blood processor 100 apparatus, but are created externally and downloaded, via the computer of the blood processor 100 , into the memory 120 of the blood processor 100 . Downloading of such instructions is performed in a manner well known to those of skill in this field.
- the act of downloading instructions or scripts into memory 120 is not the subject of this invention, and detailed description thereof will be omitted for the sake of clarity.
- an external computer 200 having a blood processor interface 210 , a script generator 220 , and a user interface 230 .
- the blood processor interface 210 provides a means whereby the script of custom interpretive language instructions may be passed from the external computer 200 to the memory 120 of the blood processor 100 .
- this aspect of the external computer 200 is not further discussed in detail.
- the script generator 220 and the user interface 230 of the external computer 200 are important in achieving the object of the invention.
- the key advantages of these components will be made apparent by first discussing a conventional way to generate instructions, and then by explaining the invention.
- a compiler may perform operations on the source code, as is well known in this field, and produce, as an output, machine language instructions. Compilers may also retrieve source code from associated files such as header files, and may retrieve machine language code from library files, as part of the operations of making machine language code corresponding to the input source code. The resulting machine language instructions may be stored in a file and downloaded to the blood processor 100 .
- a user interface 230 working cooperatively with a script generator 220 .
- the user interface 230 may be graphical in nature or not, although graphical user interface 230 s are preferred for ease of use.
- the user interface 230 and script generator 220 may be customized to the architecture of the blood processor 100 .
- the external computer 200 is depicted in FIG. 3.
- the script generator 220 contains information of three general types:
- device information 222 relating to all of the different controls, sensors, buttons, and displays of the blood processor 100 ;
- operation information 224 that is indicative of the different operations that may be performed with respect to the devices.
- limits information 226 that indicates operational limits for the operations. These three types of information may be embodied in any manner. The presently preferred manner of embodying this information is exemplified in the following description made with respect to a shield that may be automatically raised, automatically lowered, and automatically locked.
- the devices 140 associated with the shield include a stepper motor that moves the shield, a first sensor that detects the shield to be in a fully closed position, and a second sensor that detects the shield to be in a fully locked position.
- the operations information associated with the foregoing may include operations of locking or unlocking the locking mechanism, of moving the shield in a closing or an opening direction, of stopping the shield, and the like.
- the limits information 226 associated with the operations may include maximum speed of travel for the shield, maximum travel distance for the shield, and the like.
- shield_open 0 ⁇ 0020
- shield_close 0 ⁇ 0021
- shield_lock 0 ⁇ 0022
- shield_unlock 0 ⁇ 0023
- shield_up 0 ⁇ 0024
- shield_down 0 ⁇ 0025
- shield_open 0 ⁇ 0020
- shield_lock_detect 0 ⁇ 0026 . . .
- the user interface 230 might thus present a human readable form of each command from a menu, allowing the user to select from the permitted commands.
- the user might set up a script using commands such as:
- Shield Compare lock-sensor shield-locked
- Shield Close and “Shield Compare” have associated parameters.
- the Shield Close command may have a speed parameter associated with it.
- the speed parameter could be used to drive the shield stepper motor, for example, in larger or smaller steps.
- the following table shows how an interpretive language command might be provided in response to the user selecting a particular command via the user interface.
- the user has entered a command to perform an “up” operation on the device that drives the shield, which device might be a stepper motor.
- the user interface requires the user to enter the necessary parameters, such as speed of the upward movement and distance to be traveled.
- the user interface conveniently displays the units that relate to the parameters of each operation.
- Para- Para- meter Command meters values Units Human Shield up Speed 4 steps per second readable Distance 900 1/10 of mm command Interp. 0x0024, 4, 900 language command
- the “shield up” command has been formed with the speed parameter being 4 steps/s, and the distance to travel being 900 tenths of a millimeter (i.e., 9 centimeters).
- the user interface knowing that the maximum speed allowed for shield travel is 5 steps/s, does not permit the user to enter a value greater than 5 for the speed parameter.
- the maximum travel allowed may also be checked against the predetermined limit, i.e., shield_max_travel.
- the shield_up command is changed into the hexadecimal value 24 ( ⁇ 24), which is the command identifier used by the microprocessor of the blood processor.
- the microprocessor is pre-programmed to respond to the command ⁇ 24 by controlling the stepper motor that drives the shield of the blood processor to move the shield in an upward direction.
- the parameters 4 and 900 are used by the microprocessor to control the stepper motor's speed (i.e., 4 steps per second) and the number of steps actually commanded (i.e., the equivalent of 9 cm).
- the numbers 4 and 900 are preferably converted to hexadecimal values as part of the script generation. Different commands will require different numbers of parameters.
- the user interface 230 permits a user to select from different operations on corresponding devices 140 within particular limits.
- the script generator 220 takes the items and their parameters selected by the user, and produces corresponding instructions in the custom interpretive language. That is, the script generator 220 generates custom interpretive language instructions with the appropriate addresses and parameters that correspond to the set of steps selected by the user.
- the user interface 230 and script generator 220 may be combined into a single module, of course, or broken down into several modules.
- the user interface 230 and/or script generator 220 should permit the storage of scripts for later recall and modification. Once the scripts of custom interpretive language instructions are thus stored, the blood processor interface 210 may be invoked to download the script into the memory 120 of the blood processor 100 via the blood processor 100 .
- the VIVOSTATMsystem by the BRISTOL-MYERS SQUIBB company is an example of a highly complex blood processor 100 to which the invention is applicable.
- the VIVOSTAT 198 system produces autologous fibrin sealant from a patient's own blood in approximately 30 minutes.
- the apparatus includes a start button and a display panel, which are the only controls making up the man/machine interface. In other words, the user inserts a preparation unit, pushes the start button, and waits while the blood processor performs a myriad of complex operations.
- the display panel indicates progress during the processing.
- the VIVOSTATTMsystem has numerous devices, as will become evident from the following description.
- An example of some of the human-readable set of steps to accomplish the automated blood processing phase is shown in FIG. 5.
- the first column includes step numbers
- the second column includes operations (which are often descriptive of the device being operated on)
- the third column includes parameter information relating to the operations
- the fourth column includes parameter values
- the fifth column includes unit-related information to make the script more easily readable.
- the first line on FIG. 5, for example, relates to the 72 d step in a series of steps.
- the operation relates to the flywheel device.
- the operation to be precise, is a deceleration operation.
- the relevant parameters are the final speed and the deceleration rate.
- the final speed parameter is 2000 revolutions per minute.
- the rate of deceleration is 1000 RPM per second.
- the second line of FIG. 5 is the 73 d step in the series of steps.
- the device being controlled is the piston (mentioned below) of a preparation unit.
- the operation is a wait operation. In this instance, no parameters are applicable.
- citrate is transferred into a reservoir chamber of a disposable preparation unit, e.g., a unit as described in any of the above-identified ′845, ′446, or ′784 patents.
- a dissolving buffer syringe is manually placed in the preparation unit.
- the preparation unit with syringe is placed inside the VIVOSTATTMblood processor unit.
- the processor unit shield is closed.
- the preparation unit is engaged.
- a piston is moved down and enzyme (biotinylated batroxobin) is released from a cartridge inside the preparation unit into a reaction chamber of the preparation unit, e.g., as described in U.S. Pat. No. 5,830,352.
- a halogen lamp, near infrared sensor-controlled heating system within the blood processor heats the preparation unit reservoir chamber until the temperature of the blood returns to 37° C.
- the processor spins the preparation unit, separating the plasma from the cells.
- the cells aggregate on the wall of the reservoir chamber while the plasma forms an inner core.
- the piston is moved up and draws the separated plasma core from the reservoir chamber into the reaction chamber, there to mix with the enzyme.
- the piston moves to a height sufficient to draw 60ml of plasma.
- a red blood cell detector is used to ensure that no red blood cells are drawn into the reaction chamber.
- the preparation unit is brought to a standstill. Air is drawn into the reaction chamber. The piston is moved so as to compress the air, forcing all but the fibrin I polymer and residual biotinylated batroxobin into the reservoir chamber. Short spins are performed so as to remove any additional residual plasma in the fibrin I polymer.
- the dissolving buffer is released into the reaction chamber from the syringe.
- the preparation unit is rotated in one direction, and then the other, repeatedly, so as to dissolve the fibrin I in the buffer and to produce a fibrin(I) monomer solution.
- Avidin-agarose is released into the reaction chamber to act as an enzyme capture reagent.
- the preparation unit is spun intermittently and the avidin-agarose complexes with the residual biotinylated batroxobin.
- the fibrin I—enzyme complex mixture is caused to flow into a filtration chamber of the preparation unit.
- the preparation unit is spun and centrifugal force transfers the fibrin I monomer solution through an annular filter into a collection chamber of the preparation unit. Since the agarose-avidin-biotin-batroxobin enzyme complex is unable to pass through the annular filter, it remains in the filtration chamber.
- the resulting purified fibrin I monomer solution is transferred from the collection chamber of the preparation unit back into the syringe via a safety filter.
- the shield is moved out of the way and the preparation unit is disengaged.
- the fibrin I monomer solution is combined with a pH10 buffer at the site of application, thus causing polymerization of the fibrin monomer into fibrin polymer.
- the user interface 230 and script generator 220 relieve the user of the task of programming in a programming language, and generate scripts in a custom interpretive language customized to the blood processor by virtue of the information contained in the device definition file and the operation definition file.
- the custom interpretive language instructions are downloaded into the blood processor 100 via the blood processor interface 210 and the computer onboard the blood processor 100 .
- the memory 120 of the blood processor 100 is capable of storing multiple scripts. This is advantageous when combined with a barcode scanner or the like in the blood processor 100 .
- microprocessor 110 controls a barcode reader 150 to read a barcode (not shown) of preparation unit 300 .
- a first script might relate to performing processing on blood in a normal manner, the amount of blood expected being 60cc.
- a first amount of another chemical is released from the above-identified syringe into the blood, perhaps 5cc.
- a second script might relate to performing the same general process, but for the blood of a neonatal infant. It would be unsafe to draw 60cc of blood from the neonate, and so only a few cc would be drawn and used. The amount automatically dispensed from the syringe would need to be correspondingly reduced in the second script.
- the barcode reader 150 or the like in the blood processor 100 may automatically obtain an indication of whether the first script or the second script is to be executed.
- Additional scripts may be added to the blood processor so that a third script may be generated to perform blood processing in a third manner. Since the blood processor is not controlled by an ASIC, the scripts need not all be predefined; rather, scripts may be added or changed later, making the blood processor according to this embodiment of the invention especially advantageous.
- a barcode reader is not the only means by which information from the preparation unit might be provided to the blood processor. It will occur to those familiar in this field to use optical character recognition, for example, or to use another indicator such as a certain shape or color of the preparation unit.
- the term “reader” will therefore mean all of these and similar ways of indicating, on the preparation unit, a different script should be followed.
- the term “indicator” will mean the identifying indicia or shape of the preparation unit detectable by the reader.
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Materials For Medical Uses (AREA)
- Centrifugal Separators (AREA)
- Electrotherapy Devices (AREA)
- Selective Calling Equipment (AREA)
Abstract
Description
- This application is related to the following U.S. Patents, each of which is incorporated herein by reference for all purposes: 5,603,845; 5,733,446; 5,738,784; 5,830,352.
- 1. Field of the Invention
- This invention relates to a method and system for controlling a blood processor. To be more particular, this invention is especially applicable to a blood processor that produces fibrin sealant. In its most specific embodiment, the invention is a method and system for controlling a blood processor to produce autologous fibrin sealant.
- 2. Related Art
- A blood processor may be understood, in general terms, as a machine that performs some process on blood. The blood may be human blood. A simple centrifuge may thus be thought of as a primitive blood processor.
- Blood processors range in complexity from very simple to very complex. The complexity of a blood processor may be thought of as being in direct relation to the number, the kind, and the delicacy of the processes it performs.
- For example, the separation of red blood cells with a centrifuge is, by itself, a fairly simple process. A blood processor to perform only such a separation needs only relatively simple controls, such as an on/off switch, a speed setting, or the like. In a similar vein, a highly complex apparatus for processing blood might require a myriad of controls.
- Complex blood processing procedures may require several steps. The more complex a procedure is, the is more desirable it becomes to automate as much of the procedure as possible so as to avoid human error and also to promote uniformity in execution of the steps.
- To automate processing in a blood processor, it is known to include in the blood processor an application specific integrated circuit (ASIC). An ASIC is designed to control the operation of the blood processor through the several or many steps of a complex blood processing procedure. An ASIC is a reliable and useful control mechanism for automating a blood processor.
- An ASIC is disadvantageous, however, in the respect that it cannot be freely modified. In a highly complex blood processor, capable of performing many different operations and steps, this is a disadvantage because new procedures or modifications of old procedures may be desired. A blood processor with only an ASIC cannot be freely modified to execute such procedures.
- It is an object of the invention to provide a system for the convenient production and modification of the control programs that control the automated execution of blood processing procedures.
- To achieve this objective, a blood processor is provided with a computer and memory, and external to the blood processor there is provided a general purpose computer system programmed with a convenient interface for creating scripts; the general purpose computer system translates the scripts into code of a custom interpretive language adapted to be interpreted by the computer in the blood processor, and the script of custom interpretive language instructions is written into the memory of the blood processor.
- In one embodiment of the invention, multiple scripts are stored in the blood processor, and a barcode or the like on a disposable blood preparation unit indicates to the blood processor which of the multiple scripts should be invoked.
- The invention will be better understood from the following description in which an exemplary embodiment is described in detail with the aid of the accompanying figures. It is to be understood that the described embodiment is merely an example of the realization of the invention and is for explanation only. In other words, the invention is not limited in its applicability to this one example.
- FIG. 1 shows, in simplified schematic form, a preferred embodiment of the invention.
- FIG. 2 shows, in simplified schematic form, a blood processor according to the invention.
- FIG. 3 shows, in simplified schematic form, an external computer featuring a user interface and script generator according to the invention.
- FIG. 4 shows a blood processor including a bar code reader according to one embodiment of the invention.
- FIG. 5 shows an example of a part of a script according to one embodiment of the invention.
- In FIG. 1, a
blood processor 100 is provided with amicroprocessor 110 and amemory 120. Anexternal computer 200 has ablood processor interface 210, ascript generator 220, and auser interface 230. Theexternal computer 200 is linked to theblood processor 100. To be more specific, theblood processor interface 210 of theexternal computer 200 is operably linked to write information into thememory 120 of theblood processor 100. Themicroprocessor 110 accesses thememory 120 to read the script of custom interpretive language instructions. - As schematically shown in FIG. 2, the
blood processor 100 is provided with a lowlevel hardware interface 130 to which themicroprocessor 110 is operably linked. The lowlevel hardware interface 130 provides an interface whereby themicroprocessor 110 may independently control a plurality ofdevices 140 of theblood processor 100. - As used here, “devices” means sensors, detectors, motors, actuators, displays, solenoids, or the like. Control of a
device 140 may include receiving the input from a sensor or detector, driving a motor, actuator, display, or solenoid, or generally providing inputs to or taking output from anydevice 140. - In operation, the
blood processor 100 according to the invention has, inmemory 120, a program or set of programs readable by themicroprocessor 110. Themicroprocessor 110 operates according to the program read from thememory 120. Typically, an input from one of thedevices 140 will be used to initiate the blood processing procedure. For example, ablood processor 100 may have a start button. The start button is a kind ofdevice 140. The start button, when activated, may output an electrical signal in response to the activation. This electrical signal passes to the lowlevel hardware interface 130 and may be provided as an interrupt to themicroprocessor 110. - In response to the signal from the start button, the
microprocessor 110 may command the plurality ofdevices 140 in accordance with the program steps defined in thememory 120 of theblood processor 100. The program steps may be thought of as predefined scripts which themicroprocessor 110 must follow. - It will be appreciated that the scripts stored in the
memory 120 of theblood processor 100 are not generally intelligible by an unaided human. The program steps that comprise the scripts are in a custom interpretive language specially adapted to theblood processor 100. Furthermore, it will be appreciated that the scripts are not created inside theblood processor 100 apparatus, but are created externally and downloaded, via the computer of theblood processor 100, into thememory 120 of theblood processor 100. Downloading of such instructions is performed in a manner well known to those of skill in this field. The act of downloading instructions or scripts intomemory 120 is not the subject of this invention, and detailed description thereof will be omitted for the sake of clarity. - Referring back to FIG. 1, there is represented an
external computer 200 having ablood processor interface 210, ascript generator 220, and auser interface 230. As mentioned, theblood processor interface 210 provides a means whereby the script of custom interpretive language instructions may be passed from theexternal computer 200 to thememory 120 of theblood processor 100. As with the aspect of theblood processor 100 concerned with downloading, this aspect of theexternal computer 200 is not further discussed in detail. - The
script generator 220 and theuser interface 230 of theexternal computer 200 are important in achieving the object of the invention. The key advantages of these components will be made apparent by first discussing a conventional way to generate instructions, and then by explaining the invention. - It is conventional to obtain machine language instructions for execution by a
microprocessor 110 by writing source code of a human-readable programming language. Examples of human-readable programming languages are C, FORTRAN, BASIC, and C++, to name a few. The source code is typically stored on a computer-readable medium, such as a disk, and is used as an input to a compiler for the particular programming language. - A compiler may perform operations on the source code, as is well known in this field, and produce, as an output, machine language instructions. Compilers may also retrieve source code from associated files such as header files, and may retrieve machine language code from library files, as part of the operations of making machine language code corresponding to the input source code. The resulting machine language instructions may be stored in a file and downloaded to the
blood processor 100. - Having briefly described the conventional manner of obtaining a set of instructions for execution by a
microprocessor 110, an explanation will be given as to thescript generator 220 anduser interface 230 according to the invention. - According to the invention, there is provided a
user interface 230 working cooperatively with ascript generator 220. Theuser interface 230 may be graphical in nature or not, although graphical user interface 230s are preferred for ease of use. Theuser interface 230 andscript generator 220 may be customized to the architecture of theblood processor 100. - The
external computer 200 is depicted in FIG. 3. Thescript generator 220 contains information of three general types: -
device information 222 relating to all of the different controls, sensors, buttons, and displays of theblood processor 100; -
operation information 224 that is indicative of the different operations that may be performed with respect to the devices; and - limits
information 226 that indicates operational limits for the operations. These three types of information may be embodied in any manner. The presently preferred manner of embodying this information is exemplified in the following description made with respect to a shield that may be automatically raised, automatically lowered, and automatically locked. - The
devices 140 associated with the shield include a stepper motor that moves the shield, a first sensor that detects the shield to be in a fully closed position, and a second sensor that detects the shield to be in a fully locked position. - The operations information associated with the foregoing may include operations of locking or unlocking the locking mechanism, of moving the shield in a closing or an opening direction, of stopping the shield, and the like.
- The
limits information 226 associated with the operations may include maximum speed of travel for the shield, maximum travel distance for the shield, and the like. - The following table shows how several operations may be defined:
enum commands { shield_open = 0×0020, shield_close = 0×0021, shield_lock = 0×0022, shield_unlock = 0×0023, shield_up = 0×0024, shield_down = 0×0025, shield_open = 0×0020, shield_lock_detect = 0×0026 . . . - Similarly, limits may be defined as:
#define shield_max_travel = 1523 #define shield_home_position = 0 #define shield_locked = 1 #define shield_unlocked = 0 #define shield_max_travel_speed = 5 - The
user interface 230 might thus present a human readable form of each command from a menu, allowing the user to select from the permitted commands. The user might set up a script using commands such as: - Shield Close, speed=max
- Shield Lock
- Shield Compare lock-sensor, shield-locked The above commands “Shield Close” and “Shield Compare” have associated parameters. For example, the Shield Close command may have a speed parameter associated with it. The speed parameter could be used to drive the shield stepper motor, for example, in larger or smaller steps.
- The following table shows how an interpretive language command might be provided in response to the user selecting a particular command via the user interface. In the table, the user has entered a command to perform an “up” operation on the device that drives the shield, which device might be a stepper motor. The user interface requires the user to enter the necessary parameters, such as speed of the upward movement and distance to be traveled. The user interface conveniently displays the units that relate to the parameters of each operation.
Para- Para- meter Command meters values Units Human Shield up Speed 4 steps per second readable Distance 900 1/10 of mm command Interp. 0x0024, 4, 900 language command - Here, the “shield up” command has been formed with the speed parameter being 4 steps/s, and the distance to travel being 900 tenths of a millimeter (i.e., 9 centimeters). The user interface, knowing that the maximum speed allowed for shield travel is 5 steps/s, does not permit the user to enter a value greater than 5 for the speed parameter. Likewise, the maximum travel allowed may also be checked against the predetermined limit, i.e., shield_max_travel.
- In the table above, the corresponding interpretive language command is shown. In particular, the shield_up command is changed into the hexadecimal value 24 (×24), which is the command identifier used by the microprocessor of the blood processor. The microprocessor is pre-programmed to respond to the command ×24 by controlling the stepper motor that drives the shield of the blood processor to move the shield in an upward direction. The parameters 4 and 900 are used by the microprocessor to control the stepper motor's speed (i.e., 4 steps per second) and the number of steps actually commanded (i.e., the equivalent of 9 cm). The numbers 4 and 900 are preferably converted to hexadecimal values as part of the script generation. Different commands will require different numbers of parameters.
- The precise manner of making the defined commands easily readable through a
graphical user interface 230 is not the subject of this application, and will be well within the capability of those skilled in interface design. Likewise, the precise manner of embodying the devices, operations, and limits information (222, 224, 226) in a computer program also is not the subject of this application and, supplied with the above concepts, it is within the capability of the software and control systems engineer to actually study ablood processor 100 and to define a suitable set of commands and program steps. - The
user interface 230 permits a user to select from different operations on correspondingdevices 140 within particular limits. Thescript generator 220 takes the items and their parameters selected by the user, and produces corresponding instructions in the custom interpretive language. That is, thescript generator 220 generates custom interpretive language instructions with the appropriate addresses and parameters that correspond to the set of steps selected by the user. - The
user interface 230 andscript generator 220 may be combined into a single module, of course, or broken down into several modules. - Variations are possible, but the central idea is to allow the user to create a script for the
blood processor 100 without the necessity for the user to be a computer programmer. - The
user interface 230 and/orscript generator 220 should permit the storage of scripts for later recall and modification. Once the scripts of custom interpretive language instructions are thus stored, theblood processor interface 210 may be invoked to download the script into thememory 120 of theblood processor 100 via theblood processor 100. - A concrete example of a script generated according to the invention will now be described for illustration purposes only.
- The VIVOSTA™system by the BRISTOL-MYERS SQUIBB company is an example of a highly
complex blood processor 100 to which the invention is applicable. The VIVOSTAT198 system produces autologous fibrin sealant from a patient's own blood in approximately 30 minutes. The apparatus includes a start button and a display panel, which are the only controls making up the man/machine interface. In other words, the user inserts a preparation unit, pushes the start button, and waits while the blood processor performs a myriad of complex operations. The display panel indicates progress during the processing. - The VIVOSTAT™system has numerous devices, as will become evident from the following description. An example of some of the human-readable set of steps to accomplish the automated blood processing phase is shown in FIG. 5. In FIG. 5, the first column includes step numbers, the second column includes operations (which are often descriptive of the device being operated on), the third column includes parameter information relating to the operations, the fourth column includes parameter values, and the fifth column includes unit-related information to make the script more easily readable.
- The first line on FIG. 5, for example, relates to the72 d step in a series of steps. The operation relates to the flywheel device. The operation, to be precise, is a deceleration operation. The relevant parameters are the final speed and the deceleration rate. The final speed parameter is 2000 revolutions per minute. The rate of deceleration is 1000 RPM per second.
- The second line of FIG. 5 is the73 d step in the series of steps. The device being controlled is the piston (mentioned below) of a preparation unit. The operation is a wait operation. In this instance, no parameters are applicable.
- In general, to produce autologous fibrin sealant from whole blood, the following steps are taken:
- A. During a preparation phase:
- 1. Manually, citrate is transferred into a reservoir chamber of a disposable preparation unit, e.g., a unit as described in any of the above-identified ′845, ′446, or ′784 patents.
- 2. Whole blood is manually collected from the patient and directly transferred to the reservoir chamber.
- 3. A dissolving buffer syringe is manually placed in the preparation unit. The preparation unit with syringe is placed inside the VIVOSTAT™blood processor unit.
- B. During an automated processing phase:
- 4. The processor unit shield is closed. The preparation unit is engaged. A piston is moved down and enzyme (biotinylated batroxobin) is released from a cartridge inside the preparation unit into a reaction chamber of the preparation unit, e.g., as described in U.S. Pat. No. 5,830,352.
- 5. A halogen lamp, near infrared sensor-controlled heating system within the blood processor heats the preparation unit reservoir chamber until the temperature of the blood returns to 37° C.
- 6. The processor spins the preparation unit, separating the plasma from the cells. The cells aggregate on the wall of the reservoir chamber while the plasma forms an inner core.
- 7. The piston is moved up and draws the separated plasma core from the reservoir chamber into the reaction chamber, there to mix with the enzyme. The piston moves to a height sufficient to draw 60ml of plasma. A red blood cell detector is used to ensure that no red blood cells are drawn into the reaction chamber. Once mixing is complete, the preparation unit is spun at 9000 rpm, thus converting the fibrinogen into fibrin, which in this case is fibrin I, and which immediately polymerizes, the gel-like polymer being deposited on the wall of the reaction chamber in a thin film.
- 8. The preparation unit is brought to a standstill. Air is drawn into the reaction chamber. The piston is moved so as to compress the air, forcing all but the fibrin I polymer and residual biotinylated batroxobin into the reservoir chamber. Short spins are performed so as to remove any additional residual plasma in the fibrin I polymer.
- 9. The dissolving buffer is released into the reaction chamber from the syringe. The preparation unit is rotated in one direction, and then the other, repeatedly, so as to dissolve the fibrin I in the buffer and to produce a fibrin(I) monomer solution. Avidin-agarose is released into the reaction chamber to act as an enzyme capture reagent. The preparation unit is spun intermittently and the avidin-agarose complexes with the residual biotinylated batroxobin.
- 10. The fibrin I—enzyme complex mixture is caused to flow into a filtration chamber of the preparation unit. The preparation unit is spun and centrifugal force transfers the fibrin I monomer solution through an annular filter into a collection chamber of the preparation unit. Since the agarose-avidin-biotin-batroxobin enzyme complex is unable to pass through the annular filter, it remains in the filtration chamber.
- 11. The resulting purified fibrin I monomer solution is transferred from the collection chamber of the preparation unit back into the syringe via a safety filter. The shield is moved out of the way and the preparation unit is disengaged.
- C. Application phase
- 12. The fibrin I monomer solution is combined with a pH10 buffer at the site of application, thus causing polymerization of the fibrin monomer into fibrin polymer.
- It will be appreciated that the
user interface 230 andscript generator 220 relieve the user of the task of programming in a programming language, and generate scripts in a custom interpretive language customized to the blood processor by virtue of the information contained in the device definition file and the operation definition file. The custom interpretive language instructions are downloaded into theblood processor 100 via theblood processor interface 210 and the computer onboard theblood processor 100. - In another embodiment of the invention, the
memory 120 of theblood processor 100 is capable of storing multiple scripts. This is advantageous when combined with a barcode scanner or the like in theblood processor 100. In FIG. 4,microprocessor 110 controls abarcode reader 150 to read a barcode (not shown) ofpreparation unit 300. - For example, a first script might relate to performing processing on blood in a normal manner, the amount of blood expected being 60cc. In this hypothetical process, a first amount of another chemical is released from the above-identified syringe into the blood, perhaps 5cc.
- A second script might relate to performing the same general process, but for the blood of a neonatal infant. It would be unsafe to draw 60cc of blood from the neonate, and so only a few cc would be drawn and used. The amount automatically dispensed from the syringe would need to be correspondingly reduced in the second script.
- By affixing an appropriate barcode or other indicator on the
disposable preparation unit 300, thebarcode reader 150 or the like in theblood processor 100 may automatically obtain an indication of whether the first script or the second script is to be executed. - Additional scripts may be added to the blood processor so that a third script may be generated to perform blood processing in a third manner. Since the blood processor is not controlled by an ASIC, the scripts need not all be predefined; rather, scripts may be added or changed later, making the blood processor according to this embodiment of the invention especially advantageous.
- For the sake of generality, it will be appreciated that a barcode reader is not the only means by which information from the preparation unit might be provided to the blood processor. It will occur to those familiar in this field to use optical character recognition, for example, or to use another indicator such as a certain shape or color of the preparation unit. The term “reader” will therefore mean all of these and similar ways of indicating, on the preparation unit, a different script should be followed. The term “indicator” will mean the identifying indicia or shape of the preparation unit detectable by the reader.
- It is contemplated that numerous modifications may be made to the disclosed system for control of a blood processor, without departing from the spirit and scope of the invention as defined in the following claims.
Claims (5)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/302,487 US6393369B1 (en) | 1999-04-30 | 1999-04-30 | System for control of blood processor |
CA002371579A CA2371579A1 (en) | 1999-04-30 | 2000-04-18 | System for control of blood processor |
PCT/US2000/010450 WO2000066271A1 (en) | 1999-04-30 | 2000-04-18 | System for control of blood processor |
AU46468/00A AU771671B2 (en) | 1999-04-30 | 2000-04-18 | System for control of blood processor |
JP2000615148A JP2002543404A (en) | 1999-04-30 | 2000-04-18 | System for controlling a blood processing device |
EP00928198A EP1198298A4 (en) | 1999-04-30 | 2000-04-18 | System for control of blood processor |
NO20015312A NO317613B1 (en) | 1999-04-30 | 2001-10-30 | Blood processor control system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/302,487 US6393369B1 (en) | 1999-04-30 | 1999-04-30 | System for control of blood processor |
Publications (2)
Publication Number | Publication Date |
---|---|
US6393369B1 US6393369B1 (en) | 2002-05-21 |
US20020077758A1 true US20020077758A1 (en) | 2002-06-20 |
Family
ID=23167924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/302,487 Expired - Fee Related US6393369B1 (en) | 1999-04-30 | 1999-04-30 | System for control of blood processor |
Country Status (7)
Country | Link |
---|---|
US (1) | US6393369B1 (en) |
EP (1) | EP1198298A4 (en) |
JP (1) | JP2002543404A (en) |
AU (1) | AU771671B2 (en) |
CA (1) | CA2371579A1 (en) |
NO (1) | NO317613B1 (en) |
WO (1) | WO2000066271A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223176A1 (en) * | 2005-03-31 | 2006-10-05 | Evgenia Mandrusov | Integrated system for on-site cell acquisition, processing, and delivery |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069480A1 (en) * | 2001-04-28 | 2003-04-10 | Baxter International Inc. | A system and method for networking blood collection instruments within a blood collection facility |
US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
KR101623326B1 (en) | 2012-10-26 | 2016-05-20 | 백스터 코포레이션 잉글우드 | Improved work station for medical dose preparation system |
KR102078768B1 (en) | 2012-10-26 | 2020-02-19 | 백스터 코포레이션 잉글우드 | Improved image acquisition for medical dose preparation system |
JP6238005B2 (en) * | 2013-12-27 | 2017-11-29 | 日立工機株式会社 | Centrifuge |
EP4354450A3 (en) | 2014-06-30 | 2024-06-19 | Baxter Corporation Englewood | Managed medical information exchange |
US11575673B2 (en) | 2014-09-30 | 2023-02-07 | Baxter Corporation Englewood | Central user management in a distributed healthcare information management system |
US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
WO2016090091A1 (en) | 2014-12-05 | 2016-06-09 | Baxter Corporation Englewood | Dose preparation data analytics |
US11948112B2 (en) | 2015-03-03 | 2024-04-02 | Baxter Corporation Engelwood | Pharmacy workflow management with integrated alerts |
CA2985719C (en) | 2015-06-25 | 2024-03-26 | Gambro Lundia Ab | Medical device system and method having a distributed database |
US11516183B2 (en) | 2016-12-21 | 2022-11-29 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA948564B (en) * | 1993-11-19 | 1995-07-26 | Bristol Myers Squibb Co | Liquid separation apparatus and method |
BR9509860A (en) * | 1994-12-02 | 1997-09-30 | Squibb & Sons Inc | Centrifuge reagent delivery system |
US5738784A (en) * | 1994-12-02 | 1998-04-14 | E.R. Squibb & Sons, Inc. | Device for separating a blood component from blood or plasma |
US5702357A (en) * | 1995-06-07 | 1997-12-30 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods and apparatus |
US5721676A (en) * | 1995-10-18 | 1998-02-24 | Sorvall Products, L.P. | Centrifuge data communications system |
WO1998001760A2 (en) * | 1996-07-05 | 1998-01-15 | Beckman Coulter, Inc. | Automated sample processing system |
US5865718A (en) * | 1997-01-27 | 1999-02-02 | Beckman Instruments, Inc. | System and method of operating a centrifuge utilizing a protocol record database |
-
1999
- 1999-04-30 US US09/302,487 patent/US6393369B1/en not_active Expired - Fee Related
-
2000
- 2000-04-18 CA CA002371579A patent/CA2371579A1/en not_active Abandoned
- 2000-04-18 AU AU46468/00A patent/AU771671B2/en not_active Ceased
- 2000-04-18 JP JP2000615148A patent/JP2002543404A/en not_active Withdrawn
- 2000-04-18 WO PCT/US2000/010450 patent/WO2000066271A1/en active IP Right Grant
- 2000-04-18 EP EP00928198A patent/EP1198298A4/en not_active Withdrawn
-
2001
- 2001-10-30 NO NO20015312A patent/NO317613B1/en unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223176A1 (en) * | 2005-03-31 | 2006-10-05 | Evgenia Mandrusov | Integrated system for on-site cell acquisition, processing, and delivery |
US7364657B2 (en) * | 2005-03-31 | 2008-04-29 | Abbott Cardiovascular Systems Inc. | Integrated system for on-site cell acquisition, processing, and delivery |
US20080145345A1 (en) * | 2005-03-31 | 2008-06-19 | Evgenla Mandrusov | Integrated system for on-site cell acquisition, processing and delivery |
US8968991B2 (en) | 2005-03-31 | 2015-03-03 | Abbott Cardiovascular Systems Inc. | Integrated system for on-site mononuclear cell acquisition, processing and delivery |
Also Published As
Publication number | Publication date |
---|---|
JP2002543404A (en) | 2002-12-17 |
NO20015312D0 (en) | 2001-10-30 |
CA2371579A1 (en) | 2000-11-09 |
US6393369B1 (en) | 2002-05-21 |
WO2000066271A1 (en) | 2000-11-09 |
NO20015312L (en) | 2001-12-28 |
EP1198298A4 (en) | 2003-08-27 |
AU771671B2 (en) | 2004-04-01 |
EP1198298A1 (en) | 2002-04-24 |
NO317613B1 (en) | 2004-11-22 |
AU4646800A (en) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6393369B1 (en) | System for control of blood processor | |
EP2758179B1 (en) | Improved centrifuge and method | |
JP3745397B2 (en) | Separation container, annular assembly and method for separating liquid into two or more components | |
EP0739511B1 (en) | Interactive control systems for medical processing devices | |
JPH09164194A (en) | Blood treating device system | |
JP2002503258A (en) | System and method for storing, retrieving and manipulating data in a medical processing device | |
JP2014531976A5 (en) | ||
US4953075A (en) | Control system for a sample preparation system | |
JPS63315161A (en) | Method and device for separating liquid sample | |
US20020179544A1 (en) | Cell processing and fluid transfer apparatus and method of use | |
JP2010201380A (en) | Centrifugal separator | |
CN112672697A (en) | System and method for creating cell processing protocols | |
EP2498078B1 (en) | Dissolution testing apparatus | |
US5029065A (en) | Control system for a sample preparation system | |
JP5633811B2 (en) | centrifuge | |
CN209124158U (en) | A kind of blood seperator | |
AU2001296606B2 (en) | Flexible protocol generator | |
JPS6313745B2 (en) | ||
JP6379876B2 (en) | Centrifuge | |
WO2018134387A1 (en) | Immunoassay methods and devices | |
JP7274408B2 (en) | Centrifuge | |
CN209124159U (en) | A kind of automatic liquid discharging system for blood seperator | |
CN113893598A (en) | Base, motor control method and device and water treatment equipment | |
JPS62137059A (en) | Plasma sampler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARR, RAYMOND A.;REEL/FRAME:010029/0346 Effective date: 19990609 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: VIVOLUTION A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRISTOL-MYERS SQUIBB COMPANY;REEL/FRAME:020566/0385 Effective date: 20080219 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100521 |